Vigil Neuroscience (NASDAQ:VIGL) Coverage Initiated at William Blair

Investment analysts at William Blair assumed coverage on shares of Vigil Neuroscience (NASDAQ:VIGL) in a research note issued to investors on Wednesday, MarketBeat Ratings reports. The firm set an “outperform” rating on the stock.

Other equities analysts have also recently issued research reports about the stock. Guggenheim cut their target price on shares of Vigil Neuroscience from $17.00 to $16.00 and set a “buy” rating for the company in a research report on Wednesday, August 14th. JMP Securities reiterated a “market outperform” rating and issued a $22.00 target price on shares of Vigil Neuroscience in a research note on Tuesday, November 26th. Wedbush increased their price target on shares of Vigil Neuroscience from $23.00 to $24.00 and gave the stock an “outperform” rating in a research note on Friday, November 8th. Finally, HC Wainwright restated a “buy” rating and issued a $17.00 price objective on shares of Vigil Neuroscience in a report on Friday, November 8th. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $16.60.

Vigil Neuroscience Stock Performance

Vigil Neuroscience stock opened at $2.31 on Wednesday. The company has a market cap of $94.43 million, a P/E ratio of -1.12 and a beta of 1.65. Vigil Neuroscience has a one year low of $2.08 and a one year high of $6.06. The business has a fifty day moving average of $3.33 and a two-hundred day moving average of $3.60.

Institutional Trading of Vigil Neuroscience

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new stake in Vigil Neuroscience during the second quarter worth about $26,000. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vigil Neuroscience during the 2nd quarter worth approximately $87,000. Renaissance Technologies LLC lifted its holdings in shares of Vigil Neuroscience by 19.2% in the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company’s stock worth $286,000 after purchasing an additional 11,536 shares during the last quarter. Walleye Capital LLC boosted its position in Vigil Neuroscience by 334.4% during the 3rd quarter. Walleye Capital LLC now owns 119,792 shares of the company’s stock valued at $407,000 after purchasing an additional 92,217 shares during the period. Finally, Verition Fund Management LLC bought a new position in Vigil Neuroscience during the 3rd quarter worth $442,000. 83.64% of the stock is owned by institutional investors.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.